临床淋巴结阳性乳腺癌患者原发肿瘤与淋巴结转移灶的基因组分析:TAXIS研究前瞻性队列分析
在国际III期TAXIS试验中预设的队列研究,纳入89例II/III期乳腺癌患者,比较原发肿瘤与配对淋巴结转移灶的基因组复发风险和亚型。原发灶与转移灶基因组风险一致率为84.3%(Κ=0.64),但15.6%转移灶高风险而原发灶低风险,16.0%转移灶低风险而原发灶高风险;结论认为基因组检测在淋巴结组织中的适用性仍存争议。
要点
- 原发灶与淋巴结转移灶基因组风险一致率84.3%(Κ=0.64),但超过15%患者存在风险分类不一致。
- 管腔型乳腺癌中基因组亚型不一致率17.1%(Κ=0.70),基因组亚型重新分类了35.5%的临床管腔型肿瘤。
- 临床高风险患者中,转移灶基因组低风险占25.6%(Κ=0.17),原发灶低风险占31.7%(Κ=0.13)。
核心结论
- 超过15%的患者存在基因组估计风险的不一致,可能导致过度治疗或治疗不足。
- 基因组检测在淋巴结转移灶中的适用性仍存在争议。
研究设计与样本
- 国际III期TAXIS试验(NCT03513614)内的预设研究。
- 纳入来自26个欧洲中心的89例II/III期乳腺癌患者,中位年龄63岁(范围50-72岁)。
- 比较原发肿瘤与配对淋巴结转移灶组织,主要目标为比较基因组复发风险和亚型。
- 临床风险使用Adjuvant!Online工具评估,临床亚型基于激素受体和Her2检测确定。
- 一致性评估使用Cohen Kappa(Κ)。
主要发现
- 原发灶与淋巴结转移灶基因组风险一致率为84.3%(Κ=0.64)。
- 15.6%的患者淋巴结转移灶为基因组高风险而原发灶为低风险,16.0%的患者淋巴结转移灶为低风险而原发灶为高风险。
- 管腔型乳腺癌中,原发灶与淋巴结转移灶基因组亚型不一致率为17.1%(Κ=0.70)。
- 96.5%的患者被临床分类为高风险,其中淋巴结转移灶基因组低风险者占25.6%(Κ=0.17),原发灶基因组低风险者占31.7%(Κ=0.13)。
- 基因组亚型重新分类了35.5%的临床管腔型肿瘤亚型。
关键数值与推荐
- 原发灶与淋巴结转移灶基因组风险一致率84.3%(Κ=0.64)。
- 临床高风险患者中淋巴结转移灶基因组低风险占25.6%(Κ=0.17),原发灶基因组低风险占31.7%(Κ=0.13)。
- 基因组亚型重新分类临床管腔型肿瘤的比例为35.5%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Genomic tests informing systemic therapy recommendations for breast cancer (BC) were developed and validated on primary tumor (PT) tissue. Agreement of genomic tests between the PT and matched lymph node metastases (LNm) in patients with BC is currently unclear, which limits their use in nodal tissue. METHODS: Prespecified study within the international phase III TAXIS trial (NCT03513614). Tissue from PT and matched LNm were assessed with the primary objective of comparing genomic recurrence risk and subtypes. Clinical risk was assessed using the Adjuvant!Online tool and clinical subtypes were determined based on hormone receptor and Her2 testing. Agreement was assessed using Cohen's Kappa (Κ). RESULTS: Eighty-nine patients with stage II/III BC from 26 European centers were included. Median age was 63 years (range 50-72). Agreement in genomic risk between the PT and LNm was found in 84.3 % (Κ=0.64). However, 15.6 % exhibited genomic high risk in the LNm and low risk in the PT, while 16.0 % demonstrated low risk in the LNm and high risk in the PT. Genomic subtypes of PT and LNm showed disagreement in 17.1 % of patients with luminal BC (Κ=0.70). 96.5 % of patients were clinically categorized as high risk, whereas genomically, 25.6 % of them were classified as low risk in the LNm (Κ=0.17) and 31.7 % in the PT (Κ=0.13). Genomic subtyping reclassified 35.5 % of the clinically luminal tumor subtypes. CONCLUSION: Disagreement in genomically estimated risk exists in over 15 % of patients, potentially leading to over- or undertreatment. Consequently, the applicability of genomic tests in LNm remains controversial.
引用
- Knauer M, Egle D, Hayoz S, et al. Genomic profiling of primary tumor and lymph node metastasis in patients with clinically node-positive breast cancer: prospective cohort study within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101). Eur J Cancer. 2025. PMID: 40580811. doi:10.1016/j.ejca.2025.115585
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。